Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Hepatocellular Carcinoma
NCT01192971Phase 2Completed
- Sponsor
- Hengrui
- Start
- Jun 2010
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Hengrui. Primary endpoint: Time to Progression at 8 weeks. Started Jun 2010; status: completed.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01192971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01192971.